Your browser doesn't support javascript.
loading
Bone loss induced by cancer treatments in breast and prostate cancer patients.
Castañeda, Santos; Casas, Ana; González-Del-Alba, Aránzazu; Martínez-Díaz-Guerra, Guillermo; Nogués, Xavier; Ojeda Thies, Cristina; Torregrosa Suau, Óscar; Rodríguez-Lescure, Álvaro.
Afiliación
  • Castañeda S; Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Catedra UAM-Roche, EPID-Future, Universidad Autónoma de Madrid, Madrid, Spain.
  • Casas A; Department of Medical Oncology, Hospital Virgen del Rocío, Seville, Spain.
  • González-Del-Alba A; Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
  • Martínez-Díaz-Guerra G; Department of Endocrinology and Nutrition, Instituto de Investigación imas12, Universidad Complutense, Hospital 12 de Octubre, Madrid, Spain.
  • Nogués X; Department of Internal Medicine, Hospital del Mar, Hospital del Mar Research Institute (IMIM), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Universidad Pompeu Fabra, Barcelona, Spain.
  • Ojeda Thies C; Department of Traumatology and Orthopedic Surgery, Hospital Universitario, 12 de Octubre, Madrid, Spain.
  • Torregrosa Suau Ó; Department of Internal Medicine, Hospital General Universitario de Elche, Alicante, Spain.
  • Rodríguez-Lescure Á; Department of Medical Oncology, Hospital General Universitario de Elche, Camino de la Almazara, 11, 03202, Alicante, Spain. alescure@geicam.org.
Clin Transl Oncol ; 24(11): 2090-2106, 2022 Nov.
Article en En | MEDLINE | ID: mdl-35779210
Cancer and cancer therapies are a major factor risk for osteoporosis due to bone loss and deterioration of bone microarchitecture. Both factors contribute to a decrease in bone strength and, consequently, increased bone fragility and risk of fracture. Cancer-associated bone loss is a multifactorial process, and optimal interdisciplinary management of skeletal health, accurate assessment of bone density, and early diagnosis are essential when making decisions aimed at reducing bone loss and fracture risk in patients who have received or are receiving treatment for cancer. In this document, a multidisciplinary group of experts collected the latest evidence on the pathophysiology of osteoporosis and its prevention, diagnosis, and treatment with the support of the Spanish scientific society SEOM. The aim was to provide an up-to-date and in-depth view of osteoporotic risk and its consequences, and to present a series of recommendations aimed at optimizing the management of bone health in the context of cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis / Neoplasias de la Próstata / Conservadores de la Densidad Ósea Tipo de estudio: Guideline / Prognostic_studies / Screening_studies Límite: Humans / Male Idioma: En Revista: Clin Transl Oncol Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis / Neoplasias de la Próstata / Conservadores de la Densidad Ósea Tipo de estudio: Guideline / Prognostic_studies / Screening_studies Límite: Humans / Male Idioma: En Revista: Clin Transl Oncol Año: 2022 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia